EMA image

EMA ramps up adaptive pathways pilot

pharmafile | December 23, 2014 | News story | Manufacturing and Production, Research and Development, Sales and Marketing EMA, adaptive pathways, drugs, regulator 

Six medicines have been selected to move to the next stage of the EMA’s adaptive pathways pilot project, to explore new ways to give patients faster access to new drugs.

The EMA launched the trial in March, to identify candidate drugs and manufacturers to take through an adaptive pathway to licensing. The ultimate aim is to find drugs that treat serious conditions with an unmet medical need, and reduce the time to a medicine’s approval.

The Agency received 34 applications from companies to include their medicines in the adaptive pathways pilot project: six for advanced-therapy medicinal products, 12 for orphan medicines, and 14 for cancer drugs.

The successful companies will now develop their proposals, including setting out their plans for health technology assessments and acquiring real-world data on their drugs. The EMA’s report on the first phase of the pilot acknowledges that the drugs “are all cases where the development pathway and the value decisions present difficult questions”.

The EMA is also working on ways to “discuss general issues such as opportunities and hurdles to the implementation of the adaptive pathways paradigm in the different public bodies”. In the report, the Agency identifies issues including patient input and earlier involvement with health technology assessment bodies as important lessons learned that need to be addressed in the second phase.

Earlier in December a research paper published jointly by researchers from the EMA, industry the MHRA and patient groups concluded that adaptive pathways could be ‘transformative’ for the industry, patients and healthcare systems, but only if there is substantial pressure and the political will to overcome regulatory barriers.

The pilot aims to help develop an understanding of how future adaptive pathways might work for different drugs. So far the EMA says there are two scenarios under which adaptive pathways may work: granting approval for a well-defined, high medical need subgroup, and then subsequently widening the indication to include a larger patient population; or granting an early or conditional approval – for example on the basis of surrogate endpoints – and then collecting data post-approval and upgrading to ‘full’ approval once more data are available.

Lilian Anekwe

Related Content

EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …

louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European …

Latest content